Politics

Tracking how politics and policy intersect with science and health care

March For Life
Politics

As the March for Life approaches, anti-abortion leaders are rebranding as ‘pro-science.’ Scientists say otherwise

By Lev Facher and Megan Thielking

Scott Gottlieb
Politics

If the shutdown drags on at FDA, it will put anticipated new treatments in jeopardy

By Nicholas Florko and Ike Swetlitz

Politics

House Democrats launch drug pricing investigation into 12 major companies

By Lev Facher

President Trump Delivers Remarks On Lowering Drug Prices In Rose Garden
Politics

Trump falsely claims ‘drug prices declined in 2018’

By Casey Ross

Pharmalot

Pharmalittle: ‘Netflix’ model for hep C drugs proceeds; J&J hikes drug prices

By Elizabeth Cooney

Sen. Elizabeth Warren (D-MA)
Politics

As the 2020 campaign kicks off, Democrats scramble to prove their leadership on lowering drug costs

By Lev Facher

Patients for Affordable Drugs
Politics

Drug pricing advocates to spend $1M on ads supporting Trump proposal

By Lev Facher

Len Schleifer
Pharma

Regeneron CEO: ‘We need a carrot-and-stick system’ to balance pricing and innovation

By Ed Silverman and Matthew Herper

Sen. Chuck Grassley (R-IA)
Politics

As Congress returns, lawmakers rush to detail drug-pricing agendas

By Lev Facher

Peter Dejong/AP
Politics

EU Medicines Agency picks up its roots, embracing Amsterdam

By Associated Press

Pharmalot

Pharmalittle: Existing drugs driving higher prices; Baselga lands at AstraZeneca

By Elizabeth Cooney

FDA Commissioners Margaret Hamburg
Politics

All seven of the FDA’s recent commissioners agree it should be independent — but not on how to accomplish it

By Ike Swetlitz

Supreme Court
Politics

Supreme Court seems unlikely to overhaul popular drug industry legal strategy

By Ike Swetlitz

Politics

Supreme Court to examine a common legal strategy drug makers use to sidestep patient lawsuits

By Ike Swetlitz

Kelvin Droegemeier
Politics

With Senate votes, Trump gets a permanent drug czar — and his first science adviser

By Lev Facher

Pharma pays up illo
Special Report

How PhRMA finally lost: the inside story of the group’s biggest lobbying failure in years

By Nicholas Florko

HHS Health and Human Services
Hospitals

Judge blocks Trump administration cuts to 340B hospital drug-discount program

By Ike Swetlitz

3 to Watch: Legislative Battles
Politics

3 state legislative battles to watch in 2019

By Lev Facher

3 to Watch: Lawmakers
Politics

3 freshman lawmakers to watch in 2019

By Nicholas Florko

Health

NIH hospital’s pipes harbored uncommon bacteria that infected patients

By Ike Swetlitz

FDA
Politics

It’s official: parts of the government, including FDA, shut down early Saturday

By Ike Swetlitz and Erin Mershon

Ebola shake-down exercise - Dulles
Politics

In last-ditch move, lawmakers push to renew pandemic preparedness bill before end of year

By Ike Swetlitz

Sen. Orrin Hatch
Politics

Sen. Hatch to colleagues: Don’t let Trump tie drug prices to what other countries pay

By Nicholas Florko

Ron Wyden
Politics

Powerful Democrat wants Pfizer to explain price hikes for Lyrica, its nerve pain drug

By Nicholas Florko

Scott Gottlieb
Politics

As potential shutdown nears, FDA starts to prepare for furloughs

By Ike Swetlitz

Sen. Elizabeth Warren
Politics

Elizabeth Warren has a new way to lower drug prices: have the government make medicines

By Nicholas Florko

Lamar Alexander
Politics

Sen. Lamar Alexander, a leading Republican on health legislation, will not seek reelection

By Nicholas Florko

BLT mouse
Politics

A guide to fetal tissue research: the controversy, the stakes, and the hunt for alternatives

By Ike Swetlitz

NIH
Politics

NIH report scrutinizes role of China in theft of U.S. scientific research

By Lev Facher

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy